ARTICLE https://harbor-dev.pubfactory.com/view/journals/jnccn/4/1/article-p1.xml Where Are We Headed: The Value of Updating Guidelines 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/4/1/article-p2.xml The CMS 2006 Quality in Oncology Demonstration Project and NCCN Guidelines 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/4/1/article-p3.xml Surviving the Perfect Storm: An RVU-Based Model to Evaluate the Continuing Impact of MMA on the Practice of Oncology 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/4/1/article-p16.xml Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/4/1/article-p37.xml Strategies for the Treatment of Acute Promyelocytic Leukemia 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/4/1/article-p51.xml Non-Transplant Therapy for Older Adults with Acute Myeloid Leukemia 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/4/1/article-p58.xml Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/4/1/article-p78.xml Developmental Therapeutics for Myelodysplastic Syndromes 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/4/1/article-p83.xml Six (or More) Drugs in Search of a Mechanism: DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/4/1/article-p91.xml Myelodysplastic Syndromes: Iron Overload Consequences and Current Chelating Therapies 2019-01-04